IL104620A - Humanized monoclonal antibodies against human interleukin-5 - Google Patents
Humanized monoclonal antibodies against human interleukin-5Info
- Publication number
- IL104620A IL104620A IL10462093A IL10462093A IL104620A IL 104620 A IL104620 A IL 104620A IL 10462093 A IL10462093 A IL 10462093A IL 10462093 A IL10462093 A IL 10462093A IL 104620 A IL104620 A IL 104620A
- Authority
- IL
- Israel
- Prior art keywords
- monoclonal antibodies
- antibodies against
- against human
- humanized monoclonal
- human interleukin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83284292A | 1992-02-06 | 1992-02-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL104620A0 IL104620A0 (en) | 1993-06-10 |
IL104620A true IL104620A (en) | 2000-02-29 |
Family
ID=25262763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10462093A IL104620A (en) | 1992-02-06 | 1993-02-04 | Humanized monoclonal antibodies against human interleukin-5 |
Country Status (21)
Country | Link |
---|---|
US (1) | US6451982B1 (no) |
EP (1) | EP0625201A1 (no) |
JP (2) | JPH07505767A (no) |
KR (2) | KR0150060B1 (no) |
CN (1) | CN1077991A (no) |
AR (1) | AR248044A1 (no) |
AU (1) | AU683836B2 (no) |
CA (1) | CA2129445A1 (no) |
CZ (1) | CZ291039B6 (no) |
FI (1) | FI943635A (no) |
HU (1) | HUT67943A (no) |
IL (1) | IL104620A (no) |
NO (1) | NO942912L (no) |
NZ (1) | NZ249633A (no) |
PL (1) | PL176393B1 (no) |
RU (1) | RU94045919A (no) |
SG (1) | SG49597A1 (no) |
SK (1) | SK280610B6 (no) |
TN (1) | TNSN93012A1 (no) |
WO (1) | WO1993016184A1 (no) |
ZA (1) | ZA93779B (no) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ249633A (en) | 1992-02-06 | 1995-12-21 | Schering Corp | Monoclonal and humanised antibodies to interleukin-5, their production, use and methods for producing humanised antibodies. |
GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
USRE39548E1 (en) * | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
US6056957A (en) * | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
WO1996021000A2 (en) * | 1994-12-23 | 1996-07-11 | Smithkline Beecham Corporation | Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US7399837B2 (en) | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US5677280A (en) * | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5683983A (en) * | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
JP3946256B2 (ja) | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン5受容体α鎖に対する抗体 |
US6228360B1 (en) * | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
JP2005530490A (ja) * | 2002-03-29 | 2005-10-13 | シェーリング コーポレイション | インターロイキン−5に対するヒトモノクローナル抗体および方法およびこれを含む組成物 |
US7927840B2 (en) * | 2006-09-11 | 2011-04-19 | Gen Probe Incorporated | Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region |
CA2501946C (en) * | 2002-10-16 | 2014-12-23 | Gen-Probe Incorporated | Compositions and methods for detecting west nile virus |
WO2004055056A1 (en) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
EP1810690B1 (en) | 2004-10-28 | 2012-01-18 | Kyowa Hakko Kirin Co., Ltd. | Anti-IL-5 receptor antibody for use in treating endometriosis. |
US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
WO2006099875A1 (en) | 2005-03-23 | 2006-09-28 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
ES2492943T3 (es) | 2007-04-30 | 2014-09-10 | Glaxosmithkline Llc | Procedimientos de administración de anticuerpos anti-IL5 |
AU2009228163B2 (en) | 2008-03-28 | 2012-08-30 | Glaxosmithkline Llc | Methods of treatment |
EP2340317A1 (en) * | 2008-10-23 | 2011-07-06 | F. Hoffmann-La Roche AG | Determination of immunoglobulin encoding nucleid acid |
BR112013016235B1 (pt) | 2010-12-22 | 2020-03-31 | Cephalon Australia Pty Ltd | Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica |
WO2013087912A1 (en) | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
US9677018B2 (en) | 2013-01-09 | 2017-06-13 | Thyssenkrupp Industrial Solutions Ag | Process for the production of synthesis gas from hard coal |
US9815894B2 (en) | 2014-09-08 | 2017-11-14 | Cephalon, Inc. | Use of reslizumab to treat moderate to severe eosinophilic asthma |
TWI780988B (zh) | 2015-08-24 | 2022-10-11 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 生藥組成物 |
CA3064859A1 (en) | 2017-06-06 | 2018-12-13 | Glaxosmithkline Llc | Biopharmaceutical compositions and methods for pediatric patients |
JP2019026625A (ja) * | 2017-08-03 | 2019-02-21 | 日本全薬工業株式会社 | 抗イヌcd20モノクローナル抗体 |
US11224653B2 (en) | 2017-08-24 | 2022-01-18 | Cephalon, Inc. | Treatment strategy for non-responders to 100MG subcutaneous mepolizumab |
WO2019062831A1 (zh) * | 2017-09-29 | 2019-04-04 | 江苏恒瑞医药股份有限公司 | Il-5抗体、其抗原结合片段及医药用途 |
CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业(上海)股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
EP0441891A1 (en) * | 1988-11-03 | 1991-08-21 | Schering Corporation | Method of preventing or reducing eosinophilia |
US5096704A (en) | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2041271A1 (en) * | 1990-04-30 | 1991-10-31 | Bradford A. Jameson | Peptide analogs to proteins of the immunoglobin superfamily |
NZ249633A (en) | 1992-02-06 | 1995-12-21 | Schering Corp | Monoclonal and humanised antibodies to interleukin-5, their production, use and methods for producing humanised antibodies. |
-
1993
- 1993-02-04 NZ NZ249633A patent/NZ249633A/en unknown
- 1993-02-04 PL PL93304715A patent/PL176393B1/pl unknown
- 1993-02-04 AR AR93324239A patent/AR248044A1/es active
- 1993-02-04 WO PCT/US1993/000759 patent/WO1993016184A1/en not_active Application Discontinuation
- 1993-02-04 RU RU94045919/13A patent/RU94045919A/ru unknown
- 1993-02-04 SK SK918-94A patent/SK280610B6/sk unknown
- 1993-02-04 HU HU9402293A patent/HUT67943A/hu unknown
- 1993-02-04 JP JP5514104A patent/JPH07505767A/ja active Pending
- 1993-02-04 CA CA002129445A patent/CA2129445A1/en not_active Abandoned
- 1993-02-04 SG SG1996000571A patent/SG49597A1/en unknown
- 1993-02-04 KR KR1019940702711A patent/KR0150060B1/ko active
- 1993-02-04 IL IL10462093A patent/IL104620A/xx not_active IP Right Cessation
- 1993-02-04 AU AU36560/93A patent/AU683836B2/en not_active Ceased
- 1993-02-04 CZ CZ19941910A patent/CZ291039B6/cs not_active IP Right Cessation
- 1993-02-04 EP EP93905764A patent/EP0625201A1/en not_active Withdrawn
- 1993-02-04 ZA ZA93779A patent/ZA93779B/xx unknown
- 1993-02-05 CN CN93102685A patent/CN1077991A/zh active Pending
- 1993-02-05 TN TNTNSN93012A patent/TNSN93012A1/fr unknown
-
1994
- 1994-08-05 NO NO942912A patent/NO942912L/no not_active Application Discontinuation
- 1994-08-05 FI FI943635A patent/FI943635A/fi unknown
- 1994-08-06 KR KR1019940702711A patent/KR950700413A/ko not_active IP Right Cessation
-
1999
- 1999-11-11 JP JP11321698A patent/JP2000210097A/ja active Pending
-
2000
- 2000-03-28 US US09/537,911 patent/US6451982B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
SK280610B6 (sk) | 2000-05-16 |
CA2129445A1 (en) | 1993-08-07 |
SG49597A1 (en) | 1998-06-15 |
HU9402293D0 (en) | 1994-10-28 |
CZ291039B6 (cs) | 2002-12-11 |
IL104620A0 (en) | 1993-06-10 |
US6451982B1 (en) | 2002-09-17 |
KR950700413A (ko) | 1995-01-16 |
CN1077991A (zh) | 1993-11-03 |
TNSN93012A1 (fr) | 1994-03-17 |
FI943635A0 (fi) | 1994-08-05 |
HUT67943A (en) | 1995-05-29 |
FI943635A (fi) | 1994-08-05 |
CZ191094A3 (en) | 1994-12-15 |
PL176393B1 (pl) | 1999-05-31 |
WO1993016184A1 (en) | 1993-08-19 |
JPH07505767A (ja) | 1995-06-29 |
RU94045919A (ru) | 1996-11-10 |
AU3656093A (en) | 1993-09-03 |
EP0625201A1 (en) | 1994-11-23 |
ZA93779B (en) | 1993-08-05 |
AR248044A1 (es) | 1995-05-31 |
SK91894A3 (en) | 1995-02-08 |
JP2000210097A (ja) | 2000-08-02 |
NZ249633A (en) | 1995-12-21 |
KR0150060B1 (ko) | 1998-08-17 |
NO942912D0 (no) | 1994-08-05 |
AU683836B2 (en) | 1997-11-27 |
NO942912L (no) | 1994-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL104620A (en) | Humanized monoclonal antibodies against human interleukin-5 | |
AU1289795A (en) | Monoclonal antibodies specific for human interleukin-5 | |
SG48420A1 (en) | Humanized antibodies and uses thereof | |
PL311926A1 (en) | Anti-alphav-integrinic monoclonal antibodies | |
PL309249A1 (en) | Humanised antibodies against l-selectin | |
EP0823941A4 (en) | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES | |
IL108199A0 (en) | Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same | |
AU4618193A (en) | Humanized antibodies | |
EP0578515A3 (en) | Humanized monoclonal antibodies. | |
EP0580859A4 (en) | Anti-eda monoclonal antibody | |
GB8910395D0 (en) | Human monoclonal antibody and hybridoma producing the same | |
EP0683675A4 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS. | |
EP0506523A3 (en) | Monoclonal antibodies | |
EP0498767A3 (en) | Chimeric antiidiotypic monoclonal antibodies | |
IL102088A0 (en) | Me20:monoclonal antibodies and antigen for human melanoma | |
EP0508282A3 (en) | Anti-idiotypic monoclonal antibodies | |
ZA951113B (en) | Tumor assosiated monoclonal antibody 123av16 | |
HUT65480A (en) | Tumor associated monoclonal antibody 88bv59 | |
ZA912136B (en) | Anti-oncostatin m monoclonal antibodies | |
GB9212074D0 (en) | Monoclonal antibody | |
SG64332A1 (en) | Monoclonal antibody | |
AU5852094A (en) | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same | |
IE900593L (en) | Monoclonal antibodies | |
IE901210L (en) | Monoclonal antibody | |
IE900922L (en) | Monoclonal antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
RH1 | Patent not in force |